Bio-Path Holdings FY2024 net loss $9.9M; cash $1.2M; clinical progress in obesity and AML

BIO-PATH HOLDINGS, INC.

Net loss of $9.9M ($4.12 per share) vs $16.1M ($33.63 per share) in FY2023.
Cash and cash equivalents of $1.2M as of Dec 31, 2024; net cash used in operations $10.6M.
R&D expense decreased to $7.3M from $11.6M; G&A expense increased to $4.7M.
Preclinical BP1001-A shows restored insulin sensitivity; Phase 1/1b BP1002 in AML progressed to 90 mg/m² dose cohort.
Patent portfolio expanded: 7 US patents, 61 foreign patents; new patents in US and NZ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.